| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
82,110,000 |
| Market
Cap: |
3.51(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.73 - $53.69 |
|
| Level
I Sector: |
Consumer Discretionary |
| Level
II Sector: |
Leisure |
| Level
III Sector: |
Restaurants |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
| |
NASDAQ INDUSTRIAL |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
69,133 |
99,133 |
200,384 |
249,340 |
| Total Sell Value |
$3,373,178 |
$4,809,278 |
$8,291,909 |
$10,478,837 |
| Total People Sold |
8 |
8 |
9 |
12 |
| Total Sell Transactions |
10 |
11 |
20 |
34 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dier Mardi |
CFO & Executive Vice President |
• – – |
2021-10-14 |
4 |
AS |
$81.16 |
$264,663 |
D/D |
(3,261) |
38,762 |
|
-17% |
|
| Dier Mardi |
CFO & Executive Vice President |
• – – |
2021-10-12 |
4 |
AS |
$82.79 |
$287,861 |
D/D |
(3,477) |
42,023 |
|
-22% |
|
| Kassberg Thomas Richard |
CBO & EVP |
• – – |
2021-09-30 |
4 |
OE |
$0.31 |
$34,018 |
D/D |
109,734 |
216,552 |
|
- |
|
| Huizenga Theodore Alan |
SVP, Chief Accounting Officer |
• – – |
2021-09-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
819 |
14,212 |
|
- |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2021-09-08 |
4 |
S |
$100.65 |
$738,368 |
D/D |
(7,336) |
28,668 |
|
35% |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2021-09-08 |
4 |
OE |
$54.50 |
$399,812 |
D/D |
7,336 |
36,004 |
|
- |
|
| Bedrosian Camille L |
EVP and Chief Medical Officer |
• – – |
2021-09-02 |
4 |
AS |
$100.18 |
$250,450 |
D/D |
(2,500) |
38,775 |
|
-31% |
|
| Bedrosian Camille L |
EVP and Chief Medical Officer |
• – – |
2021-09-02 |
4 |
OE |
$55.00 |
$137,500 |
D/D |
2,500 |
41,275 |
|
- |
|
| Bedrosian Camille L |
EVP and Chief Medical Officer |
• – – |
2021-09-01 |
4 |
AS |
$100.03 |
$250,075 |
D/D |
(2,500) |
38,775 |
|
-29% |
|
| Bedrosian Camille L |
EVP and Chief Medical Officer |
• – – |
2021-09-01 |
4 |
OE |
$55.00 |
$137,500 |
D/D |
2,500 |
41,275 |
|
- |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2021-07-06 |
4 |
S |
$91.53 |
$34,324 |
D/D |
(375) |
25,333 |
|
12% |
|
| Sanders Corazon (corsee) D. |
Director |
– • – |
2021-06-29 |
4 |
A |
$0.00 |
$0 |
D/D |
3,895 |
3,895 |
|
- |
|
| Welch Daniel G |
Director |
– • – |
2021-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,145 |
14,445 |
|
- |
|
| Ekman Lars |
Director |
– • – |
2021-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,145 |
14,445 |
|
- |
|
| Aliski William |
Director |
– • – |
2021-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,145 |
66,849 |
|
- |
|
| Narachi Michael |
Director |
– • – |
2021-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,145 |
14,445 |
|
- |
|
| Fust Matthew K |
Director |
– • – |
2021-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,145 |
15,695 |
|
- |
|
| Dunsire Deborah |
Director |
– • – |
2021-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,145 |
12,570 |
|
- |
|
| Suliman Shehnaaz |
Director |
– • – |
2021-06-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,145 |
7,695 |
|
- |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2021-06-21 |
4 |
AS |
$94.96 |
$54,317 |
D/D |
(572) |
25,708 |
|
-14% |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2021-06-19 |
4 |
AS |
$94.63 |
$41,353 |
D/D |
(437) |
26,280 |
|
-14% |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2021-06-10 |
4 |
AS |
$100.00 |
$132,900 |
D/D |
(1,329) |
28,668 |
|
-21% |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2021-05-07 |
4 |
AS |
$113.67 |
$44,672 |
D/D |
(393) |
26,717 |
|
-16% |
|
| Pinion John Richard |
See Remarks |
• – – |
2021-05-06 |
4 |
S |
$113.69 |
$41,269 |
D/D |
(363) |
50,122 |
|
16% |
|
| Huang Dennis Karl |
EVP & Chief Tech Ops Officer |
• – – |
2021-05-06 |
4 |
S |
$113.68 |
$41,266 |
D/D |
(363) |
40,506 |
|
16% |
|
628 Records found
|
|
Page 6 of 26 |
|
|
0.45 (1.04%) 
